Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Phizer and Moderna expected to earn 32 billion from vaccines

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Dec 13, 2020 4:25pm

67 Views

Post# 32096325

RE:RE:RE:RE:RE:RE:RE:Phizer and Moderna expected to earn 32 billion from vaccines

The market valuation is so cheap it must be very enticing, I'm sure big pharma is keeping a close eye on their progress....the closer they get to a positive conclusion on the vaccine the more likely big pharma will just buy out their competition.....

bigbanktheory wrote: Saintpeter, I also was thinking about a possible buy out. Guessing results are positive, and our patents filed I'm guessing about nine months ago, this could get pretty exciting. Not only for shareholders, but for all non shareholders too. Glta

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing